← FDA DRUG APPROVALS

FDA ANDA · ANDA213390

VIGABATRIN

Sponsor: PROPEL PHARMA

APPLICATION
ANDA213390
TYPE
ANDA
ORIGINAL APPROVAL
2021-07-29
LATEST ACTION
2024-09-12
ROUTE
ORAL
DOSAGE FORM
FOR SOLUTION
MARKETING STATUS
Discontinued

Products

VIGABATRINDiscontinued
VIGABATRIN 500MG/PACKET · FOR SOLUTION · ORAL

Approval history

2024-09-12REMS · Supplement 3AP
2022-10-26Labeling · Supplement 1 · standardAP
2022-10-12REMS · Supplement 2AP
2021-07-29UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →